Stop Cycling Your GH Peptides

The 5-on/2-off schedule and the 4-to-12-week cycle are the most copied instructions in the growth hormone peptide space, and the trial record behind them is empty. This article is a protocol correction assembled from community-sourced reports and the published trial record, and it walks the growth hormone secretagogue evidence base from the desensitization clock to the year-long trials to the immunogenicity question. It is not medical advice, nothing in it is a treatment claim, and the protocols discussed are for research use only.

I · Where the cycle folklore comes from

The most common instruction in the growth hormone peptide space is also the one with the weakest provenance, because 5-on/2-off and 4-to-12-week cycles appear in protocol sheets, vendor guides, and influencer videos with no primary source attached anywhere. One prolific community educator, a knowledgeable amateur whose trial reading anchors a large slice of the peptide discourse, has made the provenance question his recurring theme, and his verdict on the protocol sheets is blunt: “A lot of the stuff that you see in peptide protocols is made-up nonsense.” [anecdotal] ¹ The schedule lore, in his telling, is pure copy-paste lineage, since “Somebody fabricated that out of thin air years ago and it’s been regurgitated endlessly since then”, [anecdotal] ¹ and the transmission chain runs on “an endless stream of copy and pastes all originating with some initial writer pulling nonsense out of their ass, like a deranged game of Chinese whispers”. [anecdotal] ¹

The pattern predates the influencer era, but the influencer era amplified it, because TikTok-adjacent figures now supply the dosing folklore that forums used to carry. A figure the community calls Dr Seeds popularized the claim that 1 mg saturates the growth hormone receptor and that 2 mg is therefore waste, a saturation doctrine the educator refutes by pointing at trials that show stronger effects past that point. ² The fake-citation problem runs alongside the dose lore, since community fact-checkers traced influencer citations that do not exist, with the retatrutide-adjacent influencer Trevor Bachmeyer and the unfindable CJC-1295 “studies” named as the public examples of the epidemic. ³ The result is a folklore ecosystem in which cycling schedules circulate for years because they look authoritative, which is how a game of Chinese whispers survives among people who read trials.

The fasting rule belongs to the same bundle, because the protocol sheets that invented the cycles also invented the fasted-dosing requirement, and the educator’s verdict on that instruction is equally short: “The recommendation to take it fasted is just wrong.” [anecdotal] ¹ The two inventions travel together in the protocol packages, which is why the evidence review that follows settles both from the same primary sources. ⁴

II · The minutes-and-hours clock of receptor desensitization

The intellectual core of the cycling doctrine is receptor burnout, the idea that continuous exposure to a secretagogue exhausts the receptor and that time off restores it, and that model is where the biology gets specific. Growth hormone secretagogues work through G protein-coupled receptors, the GHRH receptor for tesamorelin, sermorelin, and CJC-1295 and the ghrelin receptor for ipamorelin and the GHRP class, and GPCR signaling carries a well-characterized desensitization machinery. ⁵ The relevant piece is β-arrestin, the protein that docks onto an activated receptor and shuts its signaling down, and the educator’s point is that this machinery runs on a biological clock the cycle schedules ignore, since β-arrestin desensitization “happens on a timescale of minutes and hours” ⁵ before settling into a steady state in which internalization is balanced by receptor recycling. ⁵

The arithmetic then runs against the schedules, since a 12-week cycle does nothing for a process that desensitizes and reaches steady state within the first days of exposure, and it resets nothing, because the steady state is already the balanced condition the receptor maintains under continuous agonist. ⁵ The educator calls any alternative cycling plan “a futile exercise”, ¹ since no schedule built on weeks can interact with a process that equilibrates in hours, and the same logic extends to the ghrelin receptor, which behaves like the GHRH receptor on this timescale.

The universality of the burnout story is part of its weakness, because the same desensitization argument gets applied to each peptide regardless of receptor biology, and the community’s own rule of thumb mocks the reflex: “if somebody starts talking about receptor desensitization they’re bro-sciencing hard and have no clue”. [anecdotal] ⁶ The case that makes the point land is GHK-Cu, a copper-binding tripeptide that works through copper delivery without any dedicated receptor, and the educator’s note is that “GHK-Cu is particularly funny for this because it doesn’t even have a receptor that could be desensitized”. [anecdotal] ⁶ If the cycling doctrine needs a receptor to burn out, a receptorless peptide is the reductio ad absurdum that ends the argument.

III · The long trials that ran without breaks

The cycling doctrine predicts a specific failure mode, that continuous use stops working somewhere in the weeks-to-months window, and the longest trials in the class are the direct test of that prediction. Tesamorelin is the only growth hormone secretagogue with FDA approval, developed by Theratechnologies and marketed as Egrifta, ⁷ and the registration program dosed it daily: “In the clinical trials for tesa they had patients take 2mg every single day (no recommendation to take it fasted) for a year.” ⁴ A second tesamorelin trial ran 18 months on the same daily schedule. ⁴ The program was built around daily dosing because the drug was designed for daily use, no arm of either trial tested a cycling schedule, and the protocol-sheet cycles have no comparator in the registration data. ⁷ The long program also documents the on-off arc, since tesamorelin’s effects persist while dosing continues and return toward baseline on discontinuation, which the educator cites as the reason the visceral-fat outcome is an on-drug outcome. ⁴

The MK-677 record is the more pointed test, since MK-677 is the compound the folklore treats as the worst burnout offender, an oral ghrelin mimetic whose long half-life keeps the receptor engaged around the clock. The educator relays the year-long data directly, and the shape of that curve is the whole argument:

For example in a year-long trial of MK-677 (supposedly one of the baddies that is especially desensitizing due to its long action) 24-hour mean GH at baseline was 0.81 ug/l, at 6 months was 1.38ug/l, and at 12 months was 1.36ug/l.

Community educator, Reddit peptide discourse, 2025-2026

The response climbed in the first six months and held flat through month twelve, which is the opposite of the progressive decay the burnout story predicts, and the educator’s gloss on the compound is that it ran a year straight as “a 24/7 sledgehammer on that poor receptor” ⁸ without the receptor giving out. The same direction shows in the tesamorelin pharmacodynamic record, since the human data show increased GHRH receptor sensitivity after two weeks of dosing, and the educator’s reading is that tesamorelin appears to increase receptor sensitivity while breaks reduce it. ⁸

The honest counterweight belongs in the same section, because the MK-677 trials also explain why people stop the ghrelin-class drugs, and the reason has nothing to do with receptors. In the year-long elderly cohort, MK-677 increased appetite and body weight, with subcutaneous fat rising alongside, since ghrelin-receptor agonism is a feeding signal first, and the educator notes that the GHRP class adds fat mass by mechanisms independent of growth hormone. ⁹ The desensitization story fails on the data, but the fat-gain story is real, which is what separates the correction from a free pass. ⁹

IV · The training effect at day fourteen

The most counterintuitive finding in the evidence base is that the longest look at the GHRH receptor found sensitization, the direction opposite to the burnout story. A pharmacokinetic study of tesamorelin, published under PMID 25895899, followed receptor responsiveness over the first weeks of daily dosing, and by day fourteen the growth hormone response had improved with no sign of decline. ¹⁰ A receptor that answers more strongly after two weeks of continuous exposure is becoming more sensitive, and the educator describes the phenomenon as a kind of “training” effect, ⁴ since the data point toward priming, the opposite of exhaustion. ¹⁰

The pharmacodynamic record points the same way, since the human data the community cites show increased receptor sensitivity after two weeks of tesamorelin, with the response improving in both sensitivity and amplitude. ¹¹ Both readings come from the same study family and land on the same conclusion: continuous exposure to the GHRH signal does not blunt the receptor, and repeated dosing appears to push sensitivity upward. ¹¹

The practical meaning for the cycling question follows directly, because if fourteen days of daily dosing make the receptor more sensitive, the off weeks protect nothing, and a break may work against the user, since re-exposure after a gap starts from a less-primed receptor state. ⁸ The folklore assumes the receptor needs rest, while the trial record shows a receptor responding to training, the difference between a muscle that grows under load and a battery that drains, and the whole cycling project rests on the battery model. ¹⁰

V · The immunogenicity counter-argument

The cycling question has a second axis the folklore leaves untouched, because a peptide is a foreign protein and each injection is an antigen presentation event. The educator’s immunogenicity counter-argument starts from the vaccine schedule analogy, since intermittent exposure resembles booster immunization, in which each re-exposure after a gap re-arms the immune response, whereas continuous daily exposure is the pattern most likely to be tolerated. ¹² His closing question on the intermittent approach is pointed: “maybe that’s not the greatest approach with peptides?” [anecdotal] ¹²

The concern is not hypothetical, because the gray market adds its own immunogenicity risk on top of the biology. Community practice assumes that “gray peptides frequently aren’t sterile”, [anecdotal] ¹³ and the standard risk-control answer is filtration, since a 0.22-micron filter removes the aggregated protein that drives antibody formation, with the community’s stated rationale being that filtering can reduce immunogenic impurities. ¹³ The educator adds that immunizing yourself against the peptide is a real and unquantified risk of the gray market, which is the sharpest version of the argument, since an immune response to the peptide itself would end a run in a way that no receptor desensitization ever could. ¹³ The cautionary tale the community repeats is the erythropoietin story, in which prefilled syringes stored for long periods formed aggregates that triggered anti-erythropoietin autoantibodies and caused transfusion-dependent anemia in patients, and the lesson generalizes: “Syringes are not usually made for long-term storage of medications.” [anecdotal] ¹³

The antibody question then meets the efficacy question, and the trial record offers a useful baseline, because antibodies are common even on continuous dosing without efficacy loss. The community’s reading of the incretin trials is that roughly half of tirzepatide patients develop antibodies and keep the full effect, ¹⁴ which separates the immune response from the pharmacologic response, since an antibody titer is a finding and not automatically a failure. The cycling doctrine inverts that logic, because it treats the immune system as the reason to stop dosing, when the available data suggest continuous exposure is the tolerated schedule and the gaps are the re-immunization events. ¹²

VI · The dose problem under the cycle problem

The cycling doctrine does not travel alone, because the same protocol sheets that invent the schedules also set the doses, and the dose errors are the more consequential half of the package. The educator’s signature teaching is that the protocol-sheet doses for the growth hormone class sit far below the doses the clinical trials used, which is why so many people conclude that the drugs do nothing. ¹⁵ The sermorelin record makes the point cleanly, since adult trials had to push the dose to 2 mg per day for a statistically significant IGF-1 response while the circulating protocols start at a fraction of that dose. ¹⁵ His summary of the gap is a single comparison: “You’ll see serm trials run 500mcg 2x/day to boost IGF-1 by 20%. Meanwhile 2mg of tesa will boost IGF-1 over 100%.” ⁴

Tesamorelin’s dosing story is the mirror of underdosing, since 2 mg daily is the approved Egrifta dose and the dose the trials validated, ⁷ and the educator’s read is that 2 mg of tesa lands in low-dose growth hormone territory. ⁴ The ghrelin-class drugs carry the same pattern with a different shape, since the community’s teaching is that ipamorelin used alone at protocol microdoses produces little that anyone notices, whereas a microdose on top of a GHRH potentiates the GHRH signal in the combination the community calls “Kind of a 2 + 2 = 6 situation”. ¹⁵ The combination point matters for the cycling discussion, because the famous GHRH-plus-GHRP stack is two different receptor signals cooperating, which is also why the educator warns against stacking secretagogues that hit the same receptor, since “CJC and tesa are duplicative of each other”, so the advice is to “Pick a fighter bro”. [anecdotal] ⁴

The dose problem explains a social fact that the cycling doctrine gets credit for, because when a microdosed protocol fades after a few weeks, the natural conclusion is receptor burnout, when the actual story is that the dose was subtherapeutic to begin with. ¹⁵ The educator’s framing is that people “don’t notice much/any effect because they’re microdosing”, ¹⁵ which relocates the burnout narrative from the receptor to the syringe, and that relocation is the point in miniature: the schedule was folklore, and the dose was the problem. ¹⁵

VII · What continuous dosing looks like

The correction has a positive form, and it is simpler than the folklore: run the secretagogue continuously for as long as the effect is wanted, and manage the drug with labwork on a fixed monitoring schedule. The educator’s statement of the continuous position is categorical: “There’s no reason to cycle the secretagogues. You can just run them continuously for as long as you want the effect of the drug, they keep working.” ¹⁵ On the specific question of days off, his answer is equally short: “There’s no actual reason to take any days off.” ¹ The monitoring protocol replaces the calendar, because IGF-1 is the readout that tells a user whether the dose is doing anything, and his lab routine is explicit:

Get baseline IGF-1. Follow up after a month of therapy and see what effect you’re getting. Continue periodic checks after that. Adjust your approach as needed.

Community educator, Reddit peptide discourse, 2025-2026

The first-month number matters because the response is not instant, since steady-state IGF-1 takes roughly 3 to 4 weeks to arrive, ¹⁹ which makes judging a protocol at week two premature and the follow-up draw at four to six weeks the real decision point. ¹⁶ The direction of the monitoring cuts both ways, because the same IGF-1 line that catches an underdosed protocol also catches the over-responder, and the educator reports seeing people push themselves “deep into acromegaly territory using secretagogues”, including one person with an IGF-1 well over 500, [anecdotal] ¹⁷ with his verdict that running these drugs without bloodwork is “horrible and reckless advice”. [anecdotal] ¹⁷

The expectations also deserve a schedule-free frame, since month one brings water retention, and the community’s note is that “People normally gain 5-10 pounds of water weight in the month after starting tesa because growth hormone causes a lot of water retention.” [anecdotal] ¹⁹ The same honesty applies to the long view, since the visceral-fat reduction tesamorelin is known for is GH-mediated and reverses on discontinuation, which the educator frames as “requires lifelong usage” ⁴ if the goal is to keep it. The off-ramp is gentler than the steroid world, because growth hormone physiology bounces back, and the community’s line is that the class needs no PCT since endogenous levels return on discontinuation. ¹⁸ The honest close is the comparison the educator keeps making, that exogenous growth hormone at matching doses is stronger and usually cheaper, ⁴ since 2 mg of tesa approximates low-dose growth hormone therapy in a community-synthesized equivalence, ⁴ and the secretagogue path makes sense for people who want the pulsatile, physiological range, because secretagogues push within the natural range while exogenous GH goes supraphysiological. ¹⁸

This article is community-sourced protocol analysis assembled for research purposes; it is not medical advice, and it is not a treatment claim for any condition. Tesamorelin is an FDA-approved drug in a specific indication, each other compound discussed here is a research substance, and anyone handling these peptides should do so under appropriate oversight, with tested product and honest records, and continuous dosing is a research decision that carries its own monitoring obligations.